Last reviewed · How we verify
QPX7728
At a glance
| Generic name | QPX7728 |
|---|---|
| Also known as | IV |
| Sponsor | Qpex Biopharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants (PHASE1)
- A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment (PHASE1)
- Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male Participants (PHASE1)
- P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV (PHASE1)
- Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QPX7728 CI brief — competitive landscape report
- QPX7728 updates RSS · CI watch RSS
- Qpex Biopharma, Inc. portfolio CI